Title
Race/ethnicity and economic differences in cost-related medication underuse among insured adults with diabetes: The translating research into action for diabetes study

Permalink
https://escholarship.org/uc/item/35g7p03b

Journal
Diabetes Care, 31(2)

ISSN
0149-5992

Authors
Tseng, CW
Tierney, EF
Gerzoff, RB
et al.

Publication Date
2008-02-01

DOI
10.2337/dc07-1341

Peer reviewed
Race/Ethnicity and Economic Differences in Cost-Related Medication Underuse Among Insured Adults With Diabetes

The Translating Research Into Action for Diabetes Study

CHIEN-WEN TSENG, MD, MPH1,2 ANDREW J. KARTE, PHD
EDWARD F. TIERNEY, MPH3 JOHN PIETTE, PHD
ROBERT B. GERROFF, MS4 JESSE C. CROSSON, PHD5
R. ADAMS DUDLEY, MD, MBA6 QUYNH NGO-METZGER, MD, MPH7
BETH WATZFEHLER, PHD8 RICHARD CHUNG, MD9
RONALD T. ACKERMANN, MD, MPH10 CAROL M. MANGIONE, MD, MSPH11

OBJECTIVE — To examine racial/ethnic and economic variation in cost-related medication underuse among insured adults with diabetes.

RESEARCH DESIGN AND METHODS — We surveyed 5,086 participants from the multicenter Translating Research Into Action for Diabetes Study. Respondents reported whether they used less medication because of cost in the past 12 months. We examined unadjusted and adjusted rates of cost-related medication underuse, using hierarchical regression, to determine whether race/ethnicity differences still existed after accounting for economic, health, and other demographic variables.

RESULTS — Participants were 48% white, 14% African American, 14% Latino, 15% Asian/Pacific Islander, and 8% other. Overall, 14% reported cost-related medication underuse. Unadjusted rates were highest for Latinos (23%) and African Americans (17%) compared with whites (13%), Asian/Pacific Islanders (11%), and others (15%). In multivariate analyses, race/ethnicity significantly predicted cost-related medication underuse (P=0.048). However, adjusted rates were only slightly higher for Latinos (14%) than whites (10%) (P=0.026) and were not significantly different for African Americans (11%), Asian/Pacific Islanders (7%), and others (11%). Income and out-of-pocket drug costs showed the greatest differences in adjusted rates of cost-related medication underuse (15 vs. 5% for participants with income ≤$25,000 vs. >$50,000 and 24 vs. 7% for participants with out-of-pocket costs >$150 per month vs. ≤$50 per month.

CONCLUSIONS — One in seven participants reported cost-related medication underuse. Rates were highest among African Americans and Latinos but were related to lower incomes and higher out-of-pocket drug costs in these groups. Interventions to decrease racial/ethnic disparities in cost-related medication underuse should focus on decreasing financial barriers to medications.

Diabetes Care 31:261–266, 2008

Diabetes affects ~21 million U.S. adults and is most prevalent among African Americans, Latinos, American Indians, and Asian/Pacific Islanders (1). Many racial/ethnic minorities also demonstrate worse control of their diabetes than whites and poorer control of other cardiovascular risk factors such as hypertension and hyperlipidemia that are often present in individuals with diabetes (2–6). Compared with whites, nonwhites often have poorer glycemic control (African Americans, Latinos, and Asian/Pacific Islanders) (2,3), poorer blood pressure control (African Americans and Latinos) (2,4), poorer LDL control (African Americans) (2,4), and higher rates of end-stage renal disease (African Americans, Latinos, and Asian/Pacific Islanders) (5).

One potential explanation for these racial disparities in health is that medication adherence differs across racial and ethnic groups (6–8). This is especially important to examine for medication nonadherence due to cost, since high rates of cost-related underuse have been reported among individuals with diabetes, ranging from 18 to 31% for any medication (including nondiabetes medications) among those patients with drug insurance to as high as 49% in older individuals with diabetes who lack drug insurance (9–14). Regarding the impact of cost sharing, specifically on diabetes medications, between 9 and 11% of adults with diabetes report using less diabetes medications than prescribed because of cost (9,11). This leads to potentially negative impacts on health, since nonadherence to diabetes medications is associated with poorer glycemic control (9,15,16), acute care use (15,17,18), and higher mortality rates (15). Since socioeconomic factors (e.g., income) are known to affect medication use (10,19–24) and can also...
Cost-related medication underuse

vary among racial/ethnic groups, it is important to know whether any cost-related medication underuse differences by race/ethnicity remain after adjusting for economic and other demographic factors.

Prior studies on cost-related medication underuse have been mainly of older individuals with chronic illnesses (10,11,19–25), and the effect of race/ethnicity on cost-related medication underuse has been mixed. Some studies have found race/ethnicity to be a significant predictor and other studies have found it to be nonsignificant (24). However, few studies have focused specifically on individuals with diabetes (11,12,14), including adults of all ages, and many studies have compared white versus nonwhite (11,19,20,25) or analyzed only one or two, but not three, primary race/ethnicities including African Americans, Latinos, and Asian/Pacific Islanders. In this study, we examined racial/ethnic differences in cost-related medication underuse in a large cohort of racially diverse, relatively well-insured adults with diabetes and determine to what extent economic variables (e.g., income, lack of drug coverage) mitigate any differences.

RESEARCH DESIGN AND METHODS—We used data from a nationwide sample of insured adults with diabetes from the ongoing Translating Research Into Action for Diabetes (TRIAD) Study. TRIAD is a longitudinal study of individuals with diabetes in managed care plans. Details of the study design have previously been published (26). Briefly, 11,927 patients were recruited in 2000–2001 from 10 health plans serving 180,000 individuals with diabetes in California, Hawaii, Indiana, Michigan, New Jersey, Pennsylvania, and Texas. Participants were eligible if they had diabetes, were aged ≥18 years, enrolled in a TRIAD health plan for ≥18 months, had at least one health care claim during that time, received most of their care from the plan, and could complete a written or telephone survey in English or Spanish. The study excluded nursing home residents, pregnant women, and individuals unable to provide informed consent.

TRIAD participants were surveyed again in 2002–2003 (wave 2) and 2004–2005 (wave 3) (Fig. 1). Data for the current study come from the 2004–2005 wave 3 survey, in which questions were included about cost-related medication underuse. A total of 8,156 participants were potentially eligible for the wave 3 survey, representing those participants who completed the wave 2 survey and were still eligible (i.e., had not died or been admitted to nursing homes).

Figure 1—Analytic sample and response rate.

**Statistical methods**

Cost-related medication underuse in the prior 12 months (any versus none) was our dependent variable. We fit a hierarchical logistic regression model using a penalized quasi-likelihood estimation method. We used random intercepts for health plans to account for the clustered study design and correlation among participant characteristics within the 10 health plans represented among the participants (PROC GLIMMIX, SAS version 9.1). The intraclass correlation among health plans was 0.0119. Race/ethnicity, income, prescription drug coverage, and out-of-pocket drug costs were the main independent variables of interests (predictors). We used multivariate analyses models to control for potential confounding by age, sex, education, general health status (poor to excellent), and number of medications (one to five medications versus six or more medications). Monthly out-of-pocket drug costs were represented by five categories ($0–$50, $51–$100, $101–$150, and >$150 per
month based distribution across population and previous literature showing that out-of-pocket drug costs of $50 per month and $100 per month were risk factors for cost-related medication underuse [22]). Medication categories were divided into one to five versus six or more medications since participants reported their number of prescription medications with the highest category represented by “6 or more medications.” This dichotomous group also represented the median cutoff for the number of medications reported by participants (one to five medications [51%] versus six or more medications [49%]).

Duration of diabetes and four two-way interaction terms (race/ethnicity by age, sex, income, and out-of-pocket drug costs) were assessed but were not significant and were dropped for reasons of parsimony. Missing covariate values were multiply imputed using IVEware version 2.0. On average, ~6% of responses across all variables in the models were missing. Excluding income, which had the most missing data (18%), the rate of missing responses averaged 5% for all other variables. To increase interpretability of the results, we present both unadjusted and adjusted conditional predicted percents of cost-related medication underuse calculated from the multivariate models.

RESULTS

Demographics by race/ethnicity
Of 8,157 potentially eligible participants, a total of 5,753 completed interviews, 464 refused, and the remainder were ineligible or lost to follow-up (Fig. 1). Assuming that individuals unable to be contacted had the same rate of eligibility as those contacted, the CASRO (Council of American Survey Research Organizations) response rate would have been 75%. The final sample size for the analysis was 5,086, after excluding those participants who either completed a short version of the survey that omitted questions on cost-related underuse (n = 650), reported no medication use (n = 16), or for whom we could not establish membership in a participating health plan (n = 1). Two percent of all participants (n = 105) completed the survey in Spanish, and these participants represented 15% of the Latino respondents. Subjects who participated in the baseline survey but not the wave 3 survey, compared with individuals who participated in both surveys, were more likely to be nonwhite (64 vs. 52%), slightly younger (average age 63.5 vs. 64.4 years), less educated (59 vs. 47% high school education or less), and had lower income (40% with income <$20,000 vs. 40% with income <$25,000). Both groups had similar percentages of female participants (53 vs. 54%).

The study population self-reported as 48% white, 14% African American, 14% Latino, 15% Asian/Pacific Islander, and 8% other (Table 1). Whites and Asian/ Pacific Islanders typically reported the highest income and educational levels. Latinos and African Americans were the least likely to have prescription drug cov-
Cost-related medication underuse

In this large, insured, racially diverse population of adults with diabetes, one in seven respondents reported cost-related medication underuse. Given the high rates of cost-related medication underuse, even among an insured population, efforts to decrease financial barriers to medications for individuals with diabetes are clearly still needed. Since one-fourth of our participants had medical coverage but not drug benefits, one consideration would be to tie drug benefits closer to medical coverage by not offering them separately but only as a combined benefit for those with chronic diseases such as diabetes.

To our knowledge, ours is the first study to report cost-related medication underuse for three primary racial/ethnic minorities (Latinos, African Americans, and Asian/Pacific Islanders). In unadjusted rates, cost-related medication underuse was much higher among Latinos (23%) and African Americans (17%) compared with whites (13%). Thus, cost-related medication nonadherence could be an important contributor to racial/ethnic disparities in diabetes in the sense that general medication nonadherence is associated with greater diabetes-related morbidity (9,15,16–18) and mortality (15). In our study, these racial/ethnic differences in rates of cost-related medica-

### Table 2—Unadjusted and adjusted predicted percents for cost-related medication underuse*

<table>
<thead>
<tr>
<th>Reported cost-related medication underuse*</th>
<th>Unadjusted percent (%)</th>
<th>Adjusted predicted percent (95% CI)</th>
<th>P value of variable in adjusted model</th>
</tr>
</thead>
<tbody>
<tr>
<td>All participants (n = 5,086)</td>
<td>14</td>
<td>14</td>
<td>0.048</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White (reference) (n = 2,452)</td>
<td>(13)</td>
<td>(10) (8–12)</td>
<td></td>
</tr>
<tr>
<td>African American (n = 707)</td>
<td>17</td>
<td>11 (8–13)</td>
<td></td>
</tr>
<tr>
<td>Latino (n = 736)</td>
<td>23</td>
<td>14 (10–18)†</td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander (n = 782)</td>
<td>11</td>
<td>7 (5–10)</td>
<td></td>
</tr>
<tr>
<td>Other (n = 410)</td>
<td>15</td>
<td>11 (6–15)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–44</td>
<td>24</td>
<td>23 (17–29)†</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>45–64</td>
<td>17</td>
<td>15 (13–18)†</td>
<td></td>
</tr>
<tr>
<td>&gt;65 (reference)</td>
<td>(10)</td>
<td>(6) (5–7)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>18</td>
<td>12 (10–14)†</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male (reference)</td>
<td>(11)</td>
<td>8 (7–10)</td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td>0.28</td>
</tr>
<tr>
<td>Less than high school</td>
<td>15</td>
<td>9 (7–11)</td>
<td></td>
</tr>
<tr>
<td>High school graduate</td>
<td>17</td>
<td>11 (9–13)</td>
<td></td>
</tr>
<tr>
<td>Some college or higher (reference)</td>
<td>(13)</td>
<td>(10) (8–12)</td>
<td></td>
</tr>
<tr>
<td>Annual household income</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;$25,000</td>
<td>20</td>
<td>15 (12–18)†</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>$25,000 to $49,999</td>
<td>16</td>
<td>12 (9–14)†</td>
<td></td>
</tr>
<tr>
<td>$50,000 (reference)</td>
<td>(7)</td>
<td>(5) (4–7)</td>
<td></td>
</tr>
<tr>
<td>Health status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Excellent/very good (reference)</td>
<td>(8)</td>
<td>(7) (5–9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Good</td>
<td>12</td>
<td>9 (7–11)†</td>
<td></td>
</tr>
<tr>
<td>Fair/poor</td>
<td>20</td>
<td>14 (11–16)†</td>
<td></td>
</tr>
<tr>
<td>Has prescription drug benefit</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Yes (reference)</td>
<td>(13)</td>
<td>(9) (8–11)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>19</td>
<td>13 (10–16)†</td>
<td></td>
</tr>
<tr>
<td>Number of prescription medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One to five medications (reference)</td>
<td>(14)</td>
<td>(9) (7–11)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Six or more medications</td>
<td>15</td>
<td>11 (9–13)†</td>
<td></td>
</tr>
<tr>
<td>Average monthly out-of-pocket drug costs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤$50 per month</td>
<td>(9)</td>
<td>(7) (5–8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>$51 to $100 per month</td>
<td>14</td>
<td>11 (9–14)†</td>
<td></td>
</tr>
<tr>
<td>$101 to $150 per month</td>
<td>20</td>
<td>16 (12–19)†</td>
<td></td>
</tr>
<tr>
<td>&gt; $150 per month</td>
<td>29</td>
<td>24 (20–29)†</td>
<td></td>
</tr>
</tbody>
</table>

*The model included race/ethnicity, income, whether a patient had prescription drug benefits, and average monthly out-of-pocket drug costs as main predictors. The remaining variables were included as covariates (age, sex, education, self-reported health status, and the number of prescription medications). Duration of diabetes and four two-way interaction terms (race/ethnicity by age, sex, income, and out-of-pocket drug costs) were assessed but were not significant and were not included in the final model for reasons of parsimony. †Statistically significant at P < 0.05.

CONCLUSIONS—In this large, insured, racially diverse population of adults with diabetes, one in seven respondents reported cost-related medication underuse. Given the high rates of cost-related medication underuse, even among an insured population, efforts to decrease financial barriers to medications for individuals with diabetes are clearly still needed. Since one-fourth of our participants had medical coverage but not drug benefits, one consideration would be to tie drug benefits closer to medical coverage by not offering them separately but only as a combined benefit for those with chronic diseases such as diabetes.

To our knowledge, ours is the first study to report cost-related medication underuse for three primary racial/ethnic minorities (Latinos, African Americans, and Asian/Pacific Islanders). In unadjusted rates, cost-related medication underuse was much higher among Latinos (23%) and African Americans (17%) compared with whites (13%). Thus, cost-related medication nonadherence could be an important contributor to racial/ethnic disparities in diabetes in the sense that general medication nonadherence is associated with greater diabetes-related morbidity (9,15,16–18) and mortality (15). In our study, these racial/ethnic differences in rates of cost-related medica-
tion nonadherence were minimal after adjusting for economic, health, and other demographic variables. Latinos remained the only group to be significantly different from whites, and this difference in adjusted rates of cost-related medication underuse (4%) was less than those observed across categories of income (10%), out-of-pocket drug costs (17%), and age (17%). Additionally, the two-way interaction terms of “race/ethnicity by income” and “race/ethnicity by out-of-pocket drug costs” were not found to be significant predictors of cost-related underuse. These results indicate that a potential reason why we found higher rates of cost-related medication underuse among certain racial/ethnic minorities may be more due to the lower income levels and higher out-of-pocket drug costs faced by these racial/ethnic minorities and less due to racial/ethnic differences in responding to cost pressures when it comes to medication nonadherence. Therefore, interventions to decrease racial/ethnic disparities in cost-related medication underuse should focus on decreasing financial barriers to medications. As an example, Latinos and African Americans were also the least likely to have drug coverage in our study, and this was a strong predictor of cost-related nonadherence. Since all our participants had health insurance, an important policy question would be to examine whether certain minorities are less likely to have access to drug benefits or are more likely to choose health coverage without drug benefits.

Our finding that race/ethnicity is a significant but weak independent predictor of cost-related underuse would explain why the general literature on cost-related medication underuse (not necessarily in individuals with diabetes) has been split on race/ethnicity as a significant, independent predictor (24). We examined designs of previous studies, looking for commonalities in studies that did or did not find an association between race/ethnicity and cost-related medication underuse, and found no patterns in whether studies controlled for economic variables (which nearly all have), reported on only white versus nonwhite groups (11,19,20,27), and/or included African Americans (14,19,21), Latinos (14,23,27) or Asian/Pacific Islanders separately. We know of only two earlier studies (11,14) of cost-related medication underuse that included large numbers of patients with diabetes and reported on race/ethnicity. Piette et al. (11) studied only white versus nonwhite and Mojtabai et al. (14) studied African Americans and Latinos, but not Asian/Pacific Islanders, as a separate group. Neither study found race/ethnicity to be a significant predictor after adjusting for economic variables (e.g., income). Again, this supports targeting financial barriers to medications to improve medication adherence and targeting specific racial/ethnic groups if these financial barriers are more likely to exist within them.

We do not know why, after controlling for economic, health, and other demographic variables, Latinos would be at higher risk for cost-related underuse in our study. Language barrier is a reasonable hypothesis. However, too few of our Latino respondents (15%, n = 105) completed the survey in Spanish for us to analyze Spanish language as an independent predictor, and we also did not measure patient-provider language concordance. Clearly, further work in this area would be important to address this component of cost-related medication underuse attributed to race/ethnicity.

In this study, we also found younger age, female sex, being prescribed more medications, and poorer health status to be significantly correlated with cost-related medication underuse, independent of patients’ medication costs and income. This is consistent with other studies (11,20,22,24) and points to the need for further investigations to determine why these groups are more cost sensitive. For example, patients in poorer health or who are prescribed more medications are potentially among those most vulnerable to any negative health impacts of medication cost cutting. Like other studies, we found that age was one of the strongest correlates of cost-related medication nonadherence (11,20,22,24), with 23% of the youngest group (aged 18–44 years) vs. 6% of those aged ≥65 years reporting cost-related medication underuse. We can only speculate why age is consistently such a strong determinant of cost-related medication nonadherence. A possible explanation could be that younger patients may face greater competing financial demands (excluding out-of-pocket prescription costs that we controlled for), have fewer financial assets (excluding income), have greater time demands, or may be less worried about diabetes-related complications.

Limitations to this study are that all of our participants were in managed care and had health insurance, and our findings may not be generalizable to uninsured populations. However, >92% of patients with diabetes have some form of health insurance (28). It is reasonable to assume that financial barriers for uninsured individuals would be as strong or even a stronger predictor of cost-related medication underuse. A limitation of this study is that we relied on self-reported medication underuse. Clearly, there is the potential for bias in reporting due to recall error (under- or overreporting) or reluctance to admit to nonadherence with treatment (underreporting). To date, nearly all major surveys of cost-related medication underuse rely on self-reporting alone (24). We are not aware of any large-scale published studies that have measured the validity of cost-related medication underuse by self-report through comparison with claims data. Self-reporting of cost-related medication underuse has some advantages over claims data analyses. Participants can be asked to report underuse specifically due to cost, whereas claims data may not fully distinguish between cost-related nonadherence and nonadherence due to side effects or perceived lack of treatment effectiveness. In our study, we framed the question in a very clear manner asking participants to report underuse specifically to cost in the last 12 months. Our study is also a cross-sectional analysis of a longitudinal cohort with potential participants lost to follow-up, death, or ineligibility, including admission to nursing homes. The cross-sectional nature of the study allows us to measure associations and not causality.

In conclusion, this study confirms that cost remains a significant reason for treatment nonadherence, even in an insured population. Although rates of cost-related medication underuse differed by race/ethnicity, our results suggest that reducing financial barriers to medications would be an important and effective way to address this.

Acknowledgments — C.-W.T.’s effort on this project was partially supported by the Robert Wood Johnson Generalist Physician Faculty Scholars Program (no. 051085). C.M.M.’s effort on this project was partially supported by the University of California Los Angeles (UCLA) Resource Center for Minority Aging Research (P30-AG-021684) and the Drew/UCLA Project Export (P20-MD-000148). This study was jointly funded by program announcement no. 04005 from the Centers for Disease Control and Prevention (Division of
Cost-related medication underuse

Diabetes Translation) and the National Institute of Diabetes and Digestive and Kidney Diseases.

Significant contributions to this study were made by members of the TRIAD Study Group. The authors also acknowledge the participation of our health plan partners. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding organizations.

References


